Eli Lilly and Company (LLY)vsXWELL Inc. (XWEL)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
XWEL
XWELL Inc.
$1.36
-2.16%
HEALTHCARE · Cap: $9.04M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 250547% more annual revenue ($72.25B vs $28.82M). LLY leads profitability with a 35.0% profit margin vs -81.4%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
XWEL
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+59.0%
Fair Value
$0.96
Current Price
$1.36
$0.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -333.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : XWEL
XWEL has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : XWEL
The primary concerns for XWEL are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 21.37 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while XWEL is a turnaround play — different risk/reward profiles.
XWEL carries more volatility with a beta of 1.01 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 21/100), backed by strong 35.0% margins and 55.5% revenue growth. XWEL offers better value entry with a 59.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →XWELL Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
XWELL Inc., a health and wellness services company, provides spa services at airports. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?